# Cellular Rejuvenation May Reverse Age-Related Vision Loss by Sharon Rosenzweig-Lipson > "People living with age-related vision loss like the two optic neuropathies we are currently focused on, open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION), have no therapeutic options that address the underlying damage to retinal ganglion cells. With ER-100, we are testing whether we can restore these cells to a more youthful state, not just slowing vision loss but potentially reversing it." > **— Sharon Rosenzweig-Lipson**, *Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026, October 1, 2026* ## Sources and Context - **Direct publication:** [Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026](https://www.lifebiosciences.com/life-biosciences-to-present-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies-at-eyecelerator-2026/) — published October 1, 2026. - **Exact published statement:** “People living with age-related vision loss like the two optic neuropathies we are currently focused on, open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION), have no therapeutic options that address the underlying damage to retinal ganglion cells. With ER-100, we are testing whether we can restore these cells to a more youthful state, not just slowing vision loss but potentially reversing it.” - **Context and evidence boundary:** Life Biosciences announced interim Phase 1 trial data for ER-100, an investigational epigenetic-restoration therapy using controlled OSK expression. The statement is a clinical-development hypothesis, not a claim that reversal has already been demonstrated. - **Weekly source dossier:** [[research/Weekly Reminder Hunt - 2026-10-02|Weekly Reminder Hunt — October 2, 2026]] preserves the selection rationale and the other authoritative statements reviewed in the same production cycle. ## Related Articles and Collections - **Collection:** [[collections/Simple Reminders|Simple Reminders]] - **Collection:** [[collections/Machine Succession|Machine Succession]] - **Article:** [[articles/Longevity Escape Velocity|Longevity Escape Velocity]] ## Related Topics - [[wiki/Sharon Rosenzweig-Lipson|Sharon Rosenzweig-Lipson]] - [[wiki/Age Reversal|Age Reversal]] - [[wiki/Regenerative Medicine|Regenerative Medicine]] - [[wiki/Longevity Escape Velocity|Longevity Escape Velocity]] ## Share on Social Media ``` "People living with age-related vision loss like the two optic neuropathies we are currently focused on, open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION), have no therapeutic options that address the underlying damage to retinal ganglion cells. With ER-100, we are testing whether we can restore these cells to a more youthful state, not just slowing vision loss but potentially reversing it." — Sharon Rosenzweig-Lipson, Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026, October 1, 2026 https://bryantmcgill.com/simple-reminders-rosenzweig-lipson-cellular-rejuvenation-may-reverse-age-related-vision ```